Ents with nonsquamous histology and tumors with higher MET gene copy number, a randomizedOncoTargets and Therapy 2014:submit your manuscript | dovepressDovepressTable 1 Selected MeT-inhibitor clinical trials with biomarker-selected final results if availableDrug Gefitinib + ficlatuzumab Gefitinib 94 94 84 83 MeT CNG 5, 5.six months MeT CNG 5, 3.6 months MeT+, two.9 m; MeT? 1.4 m MeT+, 1.five m; MeT? 2.7 m NS difference in PFS for T versus P by MeT high expression, inferior PFS for MeT low sufferers treated with T NS distinction in PFS by MeT expression Odds ratio (OR) for response to panitumumab + rilotumumab favored MeT higher (OR four.97, P=0.028) MeT high, six.7 months MeT higher, 4.6 months Two evaluable MET-amplified individuals; one SD (two.1 months), 1 PD NR NR NR NR 8.9 months 7.four months 69 68 60 57 48 46 48 31 22 21 five.two months five.3 months three.7 months 45 33 eight.three months 7.3 months 5.8 four.four two.2 months two.6 months 10 7 three.eight months two.three months eight.5 months 6.9 months 43 40 5.six months 4.7 months MeT high, 7.4 months MeT higher, 5.5 months NR NR NR NR MeT CNG 5, 9.three months MeT CNG 5; 7.5 months MeT+, 12.5-Cyano-2-fluorobenzoic acid Chemscene six m; MeT? eight.1 m MeT+, three.8 m; MeT? 15.three m NS difference erlotinib + tivantinib erlotinib + placebo erlotinib + onartuzumab erlotinib + placebo Cetuximab/irinotecan + tivantinib (T) Cetuximab/irinotecan + placebo (P) Panitumumab + rilotumumab Panitumumab + ganitumumab Panitumumab + placebo n RR PFS Biomarker-selected PFS OS Biomarker-selected OSNR NR 82 39 74 0 1.7 months 38 24 five.six months four.two months 11.1 months eight.9 months 7.four months* 4.three months** six.six months six.2 months 15.1 months NR NR NR NR NR 12.two months 11.1 months MeT high, 11.1 months MeT high, five.7 months eCX + rilotumumab eCX + placebo Foretinib Tivantinib Placebo Cabozantinib Foretinib Cabozantinib Mitoxantrone rednisone + rilotumumab Mitoxantrone rednisone + placebo 24 61 74 28 171 93 49 5 11 14 29.four weeks 3.0 months 2.9 months 41 39 5 24 4.4 months 4.2,3-Diaminophenol manufacturer two months 71 36 1 0 1.PMID:35126464 five months 1.four months MeT+, 2.two m; MeT? 1.five m MeT+, 1.4 m; MeT? 1.four m NR NR MeT+, 7.2 m; MeT? five.0 m MeT+, three.eight m; MeT? 9.0 m NR NR NR MeT+, 9.eight m; MeT? 13.4 m MeT+, 8.9 m; MeT? not reached 14.7 months NR NR NR NR NR Cabozantinib + rosiglitazone Rilotumumab ten mg/kg Rilotumumab 20 mg/kg Foretinib 2.5 0 13 three.7 months 2.0 months 9.three months No correlation amongst MeT expression and PFS Germ-line MeT mutant 50 ORR, 20 somatic MeT mutant 14.9 months 17.6 months NRSmyth et alTumor typeSettingNSCLC Mok et alDovepress1st-line AsianSequist et al2nd-line eGFR-na esubmit your manuscript | dovepressSpigel et al2nd/3rd-line advancedColorectal cancer eng et al76 2nd-line KRAS wild type eGFR-na eeng et alChemorefractory KRAS wild sort eGFR-na eEsophagogastric cancer Oliner et al88 1st-lineShah et al2nd-lineHepatocellular cancer Santoro et al100 2nd-lineverslype et al106 Yau et al107 Prostate cancer Smith et al115 Ryan et al1st/2nd-line 1st-line1st/2nd-line Taxane-refractoryRenal cancer Choueiri et al2nd-lineSchoffski et al2nd-lineChoueiri et al1st/2nd-line Papillary renalOncoTargets and Therapy 2014:Notes: *intermittent dosing cohort; **continuous dosing cohort. Abbreviations: RR, relative risk; PFS, progression-free survival; OS, overall survival; NSCLC, non-small-cell lung cancer; NR, not reported; eGFR, epidermal growth-factor receptor; CNG, copy-number get; KRAS, Kirsten rat sarcoma; NS, no substantial; ECX, epirubicin, cisplatin, Xeloda; SD, steady disease; PD, progressive illness; ORR, overall response price; m, months.DovepressDovep.